See today's BioWorld Asia
To read the full story, subscribe or sign in.

South Korea’s Chong Kun Dang invests in startup Biorchestra targeting AD

Oct. 16, 2019
By Jihyun Kim
HONG KONG – South Korean pharmaceutical company Chong Kun Dang Holdings recently invested KRW5 billion (US$4.1 million) in Biorchestra Co. Ltd., a Korean startup based in Daejeon that aims to develop Alzheimer’s dementia treatment based on microRNA.
BioWorld Asia Financings Newco news Neurology/psychiatric Series B Asia-Pacific